Marker Therapeutics, Inc. reported a net loss of $3.2 million for the first quarter of 2026, a significant improvement compared to a net loss of $4.4 million during the same period in 2025. The company's operating expenses decreased to $4.1 million from $5.0 million year-over-year, primarily due to reduced research and development costs, which fell by 9% to $2.8 million. General and administrative expenses also decreased by 10% to $1.2 million, reflecting lower legal and professional fees. The company’s net loss per share improved to $0.16 from $0.40 in the prior year, attributed to these reductions in expenses and an increase in grant income.
Total grant income for the quarter reached $751,691, a substantial increase from $349,104 in the first quarter of 2025. This growth was driven by various grants, including contributions from the Cancer Prevention and Research Institute of Texas (CPRIT) and the National Institutes of Health (NIH). The company’s cash, cash equivalents, and restricted cash totaled approximately $15.6 million as of March 31, 2026, down from $17.0 million at the end of 2025. The decrease in cash was primarily due to cash used in operating activities, which amounted to $1.4 million for the quarter, compared to $5.5 million in the same period last year.
Marker Therapeutics has made strategic moves to enhance its operational capabilities, including a partnership with Cellipont Bioservices for the manufacturing of its lead product, MT-601. This collaboration aims to support the scale-up and production of MT-601 for clinical trials. The company continues to rely on Baylor College of Medicine for its Multi-Antigen Recognizing (MAR)-T cell products, which are central to its immuno-oncology therapies. The company’s employee headcount remains stable, with no significant changes reported in staffing levels.
Looking ahead, Marker Therapeutics anticipates continuing to incur substantial losses as it invests in research and development activities. The company expects to fund its operations into the first quarter of 2027, assuming no additional grant funds are received. Management is considering raising additional capital through equity offerings and is actively seeking new grant opportunities to support its ongoing clinical trials and operational needs. However, the company acknowledges the uncertainty surrounding its ability to secure future funding, which could impact its long-term viability.
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing non-engineered T cell therapies targeting multiple tumor antigens. Its proprietary MAR-T platform aims to treat hematological malignancies and solid tumors by expanding natural tumor-specific T cells, minimizing tumor escape and adverse effects. The company’s products include autologous and off-the-shelf therapies, with a focus on lymphoma, pancreatic cancer, AML, and MDS, leveraging broad-spectrum, cost-effective immunotherapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.